Latest Zoledronic acid Stories

Study results suggest combination treatments may be needed to stop bone loss, fuel growth Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Osteoporosis weakens bones and increases the risk patients will suffer fractures. The findings suggest combination therapy...

New Online Resource Aims to Spark Wider Implementation of Post-Fracture Prevention Programs to Reduce the Incidence and Associated Costs of Secondary Fractures WASHINGTON, March 21, 2013 /PRNewswire-USNewswire/ -- The National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of 49 member organizations from the private and non-profit sectors (in addition to four federal government liaisons) to collectively advance bone health and...

The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today. "There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic...

Provinical Governments List Aclasta on Public Drug Plans TORONTO, Nov. 22, 2012 /CNW/ - Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment...

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data from the SHOTZ trial. Results, which were presented in an oral presentation at the 2012 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Minneapolis, MN, clearly differentiate the...

Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral bisphosphonate. According to the FDA, bisphosphonates may not provide any long-term benefits while simultaneously increasing the risk of atypical femur fractures. New York, New York (PRWEB) July 16, 2012 Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral...

(Ivanhoe Newswire) -- New research shows when it comes to bone-cancer-related fractures, pain can be reduced by drug treatment, but no one drug is superior. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Severe back pain is a common symptom of multiple myeloma—a type of cancer that can cause fractures in long bones and the spine. Bisphosphonate drugs may help to reduce the occurrence of...

Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior, according to a review published in The Cochrane Library. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Multiple myeloma is a type of cancer that grows in and on bones, and can cause fractures in long bones and the spine. Severe back pain is a common symptom. Bisphosphonate drugs may help...

A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations. The FDA said doctors need to reassess which women are likely to benefit from bisphosphonates such as Fosamax, Actonel and Reclast, given the lack of concrete evidence that taking them over long periods really helps them and the possibility that they can put some...

ASBMR calls for more research to refine recommendations further The Food and Drug Administration (FDA) announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment. Bisphosphonates are a widely prescribed class of drugs that are proven to be effective in reducing common bone fractures in people with osteoporosis and at...